# Comprehensive Literature Review

## Papers to Analyze Based on Our Findings

**Version:** 1.0
**Last Updated:** December 25, 2025
**Total Papers:** 150+

---

## How to Use This Document

Each paper is categorized by:
- **Relevance:** Direct (confirms/contradicts our findings) or Related (provides context)
- **Priority:** High / Medium / Low
- **Region:** Geographic origin of research
- **Action:** What to look for when reviewing

---

## Section 1: Drug Resistance (25 Papers)

### 1.1 Foundational Drug Resistance Studies

| # | Citation | Year | Region | Relevance | Priority |
|---|----------|------|--------|-----------|----------|
| 1 | Rhee SY, et al. "Human immunodeficiency virus reverse transcriptase and protease sequence database." *Nucleic Acids Research* | 2003 | USA | Direct - Stanford HIVDB origin | High |
| 2 | Shafer RW. "Genotypic testing for HIV-1 drug resistance." *Clinical Microbiology Reviews* | 2002 | USA | Direct - Resistance interpretation | High |
| 3 | Wensing AM, et al. "2022 update of the drug resistance mutations in HIV-1." *Topics in Antiviral Medicine* | 2022 | Netherlands | Direct - Current mutation list | High |
| 4 | Clavel F, Hance AJ. "HIV drug resistance." *New England Journal of Medicine* | 2004 | France | Related - Overview | Medium |
| 5 | Kuritzkes DR. "Drug resistance in HIV-1." *Current Opinion in Virology* | 2011 | USA | Related - Mechanisms | Medium |

### 1.2 Resistance Prediction Methods

| # | Citation | Year | Region | Relevance | Priority |
|---|----------|------|--------|-----------|----------|
| 6 | Beerenwinkel N, et al. "Geno2pheno: Estimating phenotypic drug resistance from HIV-1 genotypes." *Nucleic Acids Research* | 2003 | Germany | Direct - Benchmark comparison | High |
| 7 | Prosperi MC, et al. "A novel methodology for large-scale phylogeny partition." *Nature Communications* | 2011 | Italy/UK | Related - ML for HIV | Medium |
| 8 | Riemenschneider M, et al. "Genotypic prediction of co-receptor tropism of HIV-1." *Scientific Reports* | 2016 | Germany | Direct - ML methods | High |
| 9 | Heider D, et al. "Multilabel classification for exploiting cross-resistance information in HIV-1 drug resistance prediction." *Bioinformatics* | 2013 | Germany | Direct - Cross-resistance | High |
| 10 | Obermeier M, et al. "HIV-GRADE: a publicly available, rules-based drug resistance interpretation algorithm." *Journal of the International AIDS Society* | 2012 | Germany | Direct - Benchmark | Medium |

### 1.3 Resistance Mechanisms and Evolution

| # | Citation | Year | Region | Relevance | Priority |
|---|----------|------|--------|-----------|----------|
| 11 | Menéndez-Arias L. "Molecular basis of HIV drug resistance." *Viruses* | 2021 | Spain | Direct - Structural basis | High |
| 12 | Fun A, et al. "Human immunodeficiency virus gag and protease: partners in resistance." *Retrovirology* | 2012 | Netherlands | Related - Gag-protease | Medium |
| 13 | Sampah ME, et al. "Resistance pathway analysis of RT inhibitors." *Journal of Virology* | 2018 | USA | Direct - Pathway analysis | High |
| 14 | Kühnert D, et al. "Quantifying the fitness cost of HIV-1 drug resistance mutations." *PLOS Pathogens* | 2018 | UK/Germany | Direct - Fitness costs | High |
| 15 | Theys K, et al. "Within-patient mutation frequencies reveal fitness landscapes." *PLOS Genetics* | 2018 | Belgium | Direct - Fitness landscape | High |

### 1.4 Clinical Resistance Studies

| # | Citation | Year | Region | Relevance | Priority |
|---|----------|------|--------|-----------|----------|
| 16 | Gupta RK, et al. "HIV-1 drug resistance before initiation or re-initiation of first-line ART." *Lancet Infectious Diseases* | 2018 | UK/Global | Related - Global resistance | Medium |
| 17 | Rhee SY, et al. "Geographic and temporal trends in the molecular epidemiology and genetic mechanisms of transmitted HIV-1 drug resistance." *PLOS Medicine* | 2019 | USA | Direct - Transmission | High |
| 18 | Pingen M, et al. "Evolutionary pathways of transmitted drug-resistant HIV-1." *Journal of Antimicrobial Chemotherapy* | 2014 | Netherlands | Direct - Pathways | Medium |
| 19 | Casadellà M, Paredes R. "Deep sequencing for HIV-1 clinical management." *Virus Research* | 2017 | Spain | Related - Methods | Low |
| 20 | TenoRes Study Group. "Global epidemiology of drug resistance after failure of WHO recommended first-line regimens." *Lancet Infectious Diseases* | 2016 | Global | Related - Epidemiology | Medium |

### 1.5 Integrase Inhibitor Resistance

| # | Citation | Year | Region | Relevance | Priority |
|---|----------|------|--------|-----------|----------|
| 21 | Anstett K, et al. "Dolutegravir resistance mutation R263K." *Journal of Virology* | 2017 | Canada | Direct - INI resistance | High |
| 22 | Malet I, et al. "Mutations associated with failure of raltegravir treatment." *Antimicrobial Agents and Chemotherapy* | 2008 | France | Direct - RAL resistance | Medium |
| 23 | Brenner BG, et al. "Development of HIV resistance to integrase inhibitors." *Antiviral Research* | 2021 | Canada | Direct - INI evolution | High |
| 24 | Smith SJ, et al. "Efficacies of cabotegravir and bictegravir against drug-resistant HIV-1 integrase mutants." *Retrovirology* | 2018 | USA | Direct - New INIs | Medium |
| 25 | Wijting IEA, et al. "Dolutegravir as maintenance monotherapy." *Journal of Antimicrobial Chemotherapy* | 2019 | Netherlands | Related - Clinical | Low |

---

## Section 2: CTL Escape and Immune Responses (25 Papers)

### 2.1 HLA and Disease Progression

| # | Citation | Year | Region | Relevance | Priority |
|---|----------|------|--------|-----------|----------|
| 26 | Fellay J, et al. "A whole-genome association study of major determinants for host control of HIV-1." *Science* | 2007 | Switzerland/USA | Direct - B57/B27 protection | High |
| 27 | Pereyra F, et al. "The major genetic determinants of HIV-1 control affect HLA class I peptide presentation." *Science* | 2010 | USA | Direct - HLA mechanisms | High |
| 28 | Carrington M, O'Brien SJ. "The influence of HLA genotype on AIDS." *Annual Review of Medicine* | 2003 | USA | Direct - HLA effects | High |
| 29 | Kiepiela P, et al. "Dominant influence of HLA-B in mediating the potential co-evolution of HIV and HLA." *Nature* | 2004 | South Africa | Direct - B57 in Africa | High |
| 30 | Goulder PJ, Walker BD. "HIV and HLA Class I: An Evolving Relationship." *Immunity* | 2012 | UK/USA | Direct - Review | High |

### 2.2 CTL Escape Mechanisms

| # | Citation | Year | Region | Relevance | Priority |
|---|----------|------|--------|-----------|----------|
| 31 | Crawford H, et al. "Evolution of HLA-B*5703 HIV-1 escape mutations in HLA-B*5703-positive individuals and their transmission recipients." *Journal of Experimental Medicine* | 2009 | UK/South Africa | Direct - Escape dynamics | High |
| 32 | Carlson JM, et al. "Correlates of protective cellular immunity revealed by analysis of population-level immune escape pathways in HIV-1." *Journal of Virology* | 2012 | Canada/USA | Direct - Escape pathways | High |
| 33 | Brumme ZL, et al. "Marked epitope- and allele-specific differences in rates of mutation in HIV-1 gag, pol, and nef CTL epitopes." *Journal of Virology* | 2008 | Canada | Direct - Mutation rates | High |
| 34 | Fryer HR, et al. "Modelling the evolution and spread of HIV immune escape mutants." *PLOS Pathogens* | 2010 | UK | Direct - Modeling | Medium |
| 35 | Goepfert PA, et al. "Transmission of HIV-1 Gag immune escape mutations is associated with reduced viral load in linked recipients." *Journal of Experimental Medicine* | 2008 | USA | Direct - Transmission | Medium |

### 2.3 Epitope Studies

| # | Citation | Year | Region | Relevance | Priority |
|---|----------|------|--------|-----------|----------|
| 36 | Goulder PJ, Watkins DI. "HIV and SIV CTL escape: implications for vaccine design." *Nature Reviews Immunology* | 2004 | UK/USA | Direct - Vaccine implications | High |
| 37 | Feeney ME, et al. "Immune escape precedes breakthrough HIV-1 viremia and broadening of CTL response." *Nature Medicine* | 2004 | USA | Direct - Escape timing | Medium |
| 38 | Leslie AJ, et al. "HIV evolution: CTL escape mutation and reversion after transmission." *Nature Medicine* | 2004 | South Africa/UK | Direct - Reversion | High |
| 39 | Ganusov VV, et al. "Fitness costs and diversity of CTL response determine the rate of CTL escape during acute and chronic phases of HIV infection." *Journal of Virology* | 2011 | USA | Direct - Fitness costs | High |
| 40 | Liu MK, et al. "Vertical T cell immunodominance and epitope entropy determine HIV-1 escape." *Journal of Clinical Investigation* | 2013 | UK | Direct - Immunodominance | Medium |

### 2.4 Gag-Specific Responses

| # | Citation | Year | Region | Relevance | Priority |
|---|----------|------|--------|-----------|----------|
| 41 | Kiepiela P, et al. "CD8+ T-cell responses to different HIV proteins have discordant associations with viral load." *Nature Medicine* | 2007 | South Africa | Direct - Gag importance | High |
| 42 | Mothe B, et al. "Definition of the viral targets of protective HIV-1-specific T cell responses." *Journal of Translational Medicine* | 2011 | Spain | Direct - Protective targets | High |
| 43 | Rolland M, et al. "Broad and Gag-biased HIV-1 epitope repertoires are associated with lower viral loads." *PLOS ONE* | 2008 | USA | Direct - Breadth vs load | Medium |
| 44 | Murakoshi H, et al. "Accumulation of pol mutations selected by HLA-B*52:01-C*12:02 in controllers and progressors." *AIDS* | 2018 | Japan | Direct - Pol mutations | Medium |
| 45 | Mothe B, et al. "CTL responses of high functional avidity and broad variant cross-reactivity are associated with HIV control." *PLOS ONE* | 2012 | Spain | Direct - Functional avidity | Medium |

### 2.5 Elite Controllers

| # | Citation | Year | Region | Relevance | Priority |
|---|----------|------|--------|-----------|----------|
| 46 | Migueles SA, et al. "HLA B*5701 is highly associated with restriction of virus replication in a subgroup of HIV-infected long term nonprogressors." *PNAS* | 2000 | USA | Direct - LTNP | High |
| 47 | Hersperger AR, et al. "Perforin expression directly ex vivo by HIV-specific CD8 T-cells is a correlate of HIV elite control." *PLOS Pathogens* | 2010 | USA | Direct - Mechanisms | Medium |
| 48 | Sáez-Cirión A, et al. "HIV controllers exhibit potent CD8 T cell capacity to suppress HIV infection ex vivo." *Journal of Virology* | 2007 | France | Direct - CD8 capacity | Medium |
| 49 | Jiang C, et al. "Distinct viral reservoirs in individuals with spontaneous control of HIV-1." *Nature* | 2020 | USA | Related - Reservoirs | Medium |
| 50 | Collins DR, et al. "Functional impairment of HIV-specific CD8+ T cells precedes aborted spontaneous control of viremia." *Immunity* | 2021 | USA | Related - Progression | Low |

---

## Section 3: Broadly Neutralizing Antibodies (25 Papers)

### 3.1 bnAb Discovery and Characterization

| # | Citation | Year | Region | Relevance | Priority |
|---|----------|------|--------|-----------|----------|
| 51 | Walker LM, et al. "Broad and potent neutralizing antibodies from an African donor reveal a new HIV-1 vaccine target." *Science* | 2009 | USA/Africa | Direct - PG9/PG16 | High |
| 52 | Wu X, et al. "Rational design of envelope identifies broadly neutralizing human monoclonal antibodies to HIV-1." *Science* | 2010 | USA | Direct - VRC01 | High |
| 53 | Scheid JF, et al. "Sequence and structural convergence of broad and potent HIV antibodies that mimic CD4 binding." *Science* | 2011 | USA | Direct - 3BNC117 | High |
| 54 | Huang J, et al. "Broad and potent neutralization of HIV-1 by a gp41-specific human antibody." *Nature* | 2012 | USA | Direct - 10E8 | High |
| 55 | Mouquet H, et al. "Complex-type N-glycan recognition by potent broadly neutralizing HIV antibodies." *PNAS* | 2012 | USA | Direct - Glycan bnAbs | High |

### 3.2 bnAb Epitope Classes

| # | Citation | Year | Region | Relevance | Priority |
|---|----------|------|--------|-----------|----------|
| 56 | Burton DR, Hangartner L. "Broadly Neutralizing Antibodies to HIV and Their Role in Vaccine Design." *Annual Review of Immunology* | 2016 | USA | Direct - Review | High |
| 57 | Sok D, Burton DR. "Recent progress in broadly neutralizing antibodies to HIV." *Nature Immunology* | 2018 | USA | Direct - Current state | High |
| 58 | Kwong PD, Mascola JR. "HIV-1 Vaccines Based on Antibody Identification, B Cell Ontogeny, and Epitope Structure." *Immunity* | 2018 | USA | Direct - Vaccine design | High |
| 59 | Haynes BF, Burton DR. "Developing an HIV vaccine." *Science* | 2017 | USA | Related - Overview | Medium |
| 60 | Ward AB, Wilson IA. "The HIV-1 envelope glycoprotein structure: nailing down a moving target." *Immunological Reviews* | 2017 | USA | Direct - Structure | Medium |

### 3.3 Neutralization Breadth Studies

| # | Citation | Year | Region | Relevance | Priority |
|---|----------|------|--------|-----------|----------|
| 61 | Hraber P, et al. "Prevalence of broadly neutralizing antibody responses during chronic HIV-1 infection." *AIDS* | 2014 | USA | Direct - Prevalence | High |
| 62 | Landais E, et al. "Broadly neutralizing antibody responses in a large longitudinal sub-Saharan HIV primary infection cohort." *PLOS Pathogens* | 2016 | South Africa | Direct - Development | High |
| 63 | Doria-Rose NA, et al. "Developmental pathway for potent V1V2-directed HIV-neutralizing antibodies." *Nature* | 2014 | USA | Direct - Development | Medium |
| 64 | Bonsignori M, et al. "Maturation pathway from germline to broad HIV-1 neutralizer of a CD4-mimic antibody." *Cell* | 2016 | USA | Direct - Maturation | Medium |
| 65 | Wibmer CK, et al. "Viral escape from HIV-1 neutralizing antibodies drives increased plasma neutralization breadth through sequential recognition of multiple epitopes." *PLOS Pathogens* | 2013 | South Africa | Direct - Breadth evolution | High |

### 3.4 Clinical bnAb Studies

| # | Citation | Year | Region | Relevance | Priority |
|---|----------|------|--------|-----------|----------|
| 66 | Caskey M, et al. "Antibody 10-1074 suppresses viremia in HIV-1-infected individuals." *Nature Medicine* | 2017 | USA | Direct - Clinical | High |
| 67 | Bar-On Y, et al. "Safety and antiviral activity of combination HIV-1 broadly neutralizing antibodies in viremic individuals." *Nature Medicine* | 2018 | USA | Direct - Combinations | High |
| 68 | Mendoza P, et al. "Combination therapy with anti-HIV-1 antibodies maintains viral suppression." *Nature* | 2018 | USA | Direct - Maintenance | High |
| 69 | Corey L, et al. "Two randomized trials of neutralizing antibodies to prevent HIV-1 acquisition." *New England Journal of Medicine* | 2021 | USA | Direct - Prevention | High |
| 70 | Gilbert PB, et al. "Neutralization titer biomarker for antibody-mediated prevention of HIV-1 acquisition." *Nature Medicine* | 2022 | USA | Direct - Correlates | High |

### 3.5 Resistance and Escape

| # | Citation | Year | Region | Relevance | Priority |
|---|----------|------|--------|-----------|----------|
| 71 | Lynch RM, et al. "HIV-1 fitness cost associated with escape from the VRC01 class of CD4 binding site neutralizing antibodies." *Journal of Virology* | 2015 | USA | Direct - Fitness costs | High |
| 72 | Dingens AS, et al. "Comprehensive mapping of HIV-1 escape from a broadly neutralizing antibody." *Cell Host & Microbe* | 2017 | USA | Direct - Escape mapping | High |
| 73 | Wagh K, et al. "Potential of conventional & bispecific broadly neutralizing antibodies for prevention of HIV-1 subtype A, C & D infections." *PLOS Pathogens* | 2018 | USA | Direct - Subtype coverage | Medium |
| 74 | Schommers P, et al. "Restriction of HIV-1 escape by a highly broad and potent neutralizing antibody." *Cell* | 2020 | Germany | Direct - Broad bnAb | Medium |
| 75 | Bricault CA, et al. "HIV-1 neutralizing antibody signatures and application to epitope-targeted vaccine design." *Cell Host & Microbe* | 2019 | USA | Direct - Signatures | Medium |

---

## Section 4: Tropism and Coreceptor Usage (20 Papers)

### 4.1 Foundational Tropism Studies

| # | Citation | Year | Region | Relevance | Priority |
|---|----------|------|--------|-----------|----------|
| 76 | Fouchier RA, et al. "Phenotype-associated sequence variation in the third variable domain of the HIV-1 gp120 molecule." *Journal of Virology* | 1992 | Netherlands | Direct - 11/25 rule | High |
| 77 | Hartley O, et al. "V3: HIV's switch-hitter." *AIDS Research and Human Retroviruses* | 2005 | Switzerland | Direct - V3 review | High |
| 78 | Mild M, et al. "Differences in molecular evolution between switch (R5 to R5X4/X4-tropic) and non-switch (R5-tropic) HIV-1 populations during infection." *Infection, Genetics and Evolution* | 2010 | Sweden | Direct - Switch dynamics | High |
| 79 | Regoes RR, Bonhoeffer S. "The HIV coreceptor switch: a population dynamical perspective." *Trends in Microbiology* | 2005 | Switzerland | Direct - Population dynamics | Medium |
| 80 | Koot M, et al. "Prognostic value of HIV-1 syncytium-inducing phenotype for rate of CD4+ cell depletion and progression to AIDS." *Annals of Internal Medicine* | 1993 | Netherlands | Direct - Clinical significance | Medium |

### 4.2 Tropism Prediction Methods

| # | Citation | Year | Region | Relevance | Priority |
|---|----------|------|--------|-----------|----------|
| 81 | Lengauer T, et al. "Bioinformatics prediction of HIV coreceptor usage." *Nature Biotechnology* | 2007 | Germany | Direct - geno2pheno | High |
| 82 | Jensen MA, et al. "Improved coreceptor usage prediction and genotypic monitoring of R5-to-X4 transition by motif analysis of HIV-1 env V3 loop sequences." *Journal of Virology* | 2003 | USA | Direct - PSSM method | High |
| 83 | Sander O, et al. "Structural descriptors of gp120 V3 loop for the prediction of HIV-1 coreceptor usage." *PLOS Computational Biology* | 2007 | Germany | Direct - Structural | Medium |
| 84 | Sing T, et al. "Predicting HIV coreceptor usage on the basis of genetic and clinical covariates." *Antiviral Therapy* | 2007 | Germany | Direct - Clinical factors | Medium |
| 85 | Thielen A, et al. "Improved prediction of HIV-1 coreceptor usage with sequence information from the second hypervariable loop of gp120." *Journal of Infectious Diseases* | 2010 | Germany | Direct - V2 addition | Medium |

### 4.3 Structural and Mechanistic Studies

| # | Citation | Year | Region | Relevance | Priority |
|---|----------|------|--------|-----------|----------|
| 86 | Huang CC, et al. "Structures of the CCR5 N terminus and of a tyrosine-sulfated antibody with HIV-1 gp120 and CD4." *Science* | 2007 | USA | Direct - CCR5 structure | High |
| 87 | Cormier EG, Dragic T. "The crown and stem of the V3 loop play distinct roles in HIV-1 envelope glycoprotein interactions with CCR5." *Journal of Virology* | 2002 | USA | Direct - V3 function | High |
| 88 | Pollakis G, et al. "N-linked glycosylation of the HIV type-1 gp120 envelope glycoprotein as a major determinant of CCR5 and CXCR4 coreceptor utilization." *Journal of Biological Chemistry* | 2001 | Netherlands | Direct - Glycosylation | Medium |
| 89 | Roche M, et al. "A common mechanism of clinical HIV-1 resistance to the CCR5 antagonist maraviroc despite divergent resistance levels and lack of common gp120 resistance mutations." *Retrovirology* | 2013 | Australia | Direct - MVC resistance | Medium |
| 90 | Yuan Y, et al. "Characterization of the multiple conformational states of free and CCR5-bound HIV-1 gp120." *Nature Communications* | 2019 | China/USA | Direct - Conformations | Medium |

### 4.4 Clinical Tropism Studies

| # | Citation | Year | Region | Relevance | Priority |
|---|----------|------|--------|-----------|----------|
| 91 | Gulick RM, et al. "Maraviroc for previously treated patients with R5 HIV-1 infection." *New England Journal of Medicine* | 2008 | USA | Direct - MVC clinical | High |
| 92 | Saag M, et al. "A double-blind, placebo-controlled trial of maraviroc in treatment-experienced patients infected with non-R5 HIV-1." *Journal of Infectious Diseases* | 2009 | USA | Direct - Non-R5 | Medium |
| 93 | Swenson LC, et al. "Deep sequencing to infer HIV-1 co-receptor usage: application to three clinical trials of maraviroc in treatment-experienced patients." *Journal of Infectious Diseases* | 2011 | Canada | Direct - Deep sequencing | Medium |
| 94 | Raymond S, et al. "Genotypic prediction of HIV-1 CRF02-AG tropism." *Journal of Clinical Microbiology* | 2013 | France | Direct - CRF02 | Medium |
| 95 | McGovern RA, et al. "Population-based sequencing of the V3-loop can predict the virological response to maraviroc in treatment-naive patients of the MERIT trial." *Journal of Acquired Immune Deficiency Syndromes* | 2012 | Canada | Direct - Prediction | Medium |

---

## Section 5: Hyperbolic and Geometric Methods in Biology (15 Papers)

### 5.1 Hyperbolic Embeddings

| # | Citation | Year | Region | Relevance | Priority |
|---|----------|------|--------|-----------|----------|
| 96 | Nickel M, Kiela D. "Poincaré embeddings for learning hierarchical representations." *NeurIPS* | 2017 | USA/UK | Direct - Method basis | High |
| 97 | Ganea O, et al. "Hyperbolic neural networks." *NeurIPS* | 2018 | Switzerland | Direct - HNN | High |
| 98 | Chami I, et al. "Hyperbolic graph convolutional neural networks." *NeurIPS* | 2019 | USA | Direct - Graph methods | Medium |
| 99 | Nickel M, Kiela D. "Learning continuous hierarchies in the Lorentz model of hyperbolic geometry." *ICML* | 2018 | USA/UK | Direct - Lorentz model | Medium |
| 100 | Sala F, et al. "Representation tradeoffs for hyperbolic embeddings." *ICML* | 2018 | USA | Direct - Tradeoffs | Medium |

### 5.2 Geometric Methods for Phylogenetics

| # | Citation | Year | Region | Relevance | Priority |
|---|----------|------|--------|-----------|----------|
| 101 | Macaulay M, Darling AE. "Phylogenetic embedding in hyperbolic space." *bioRxiv* | 2020 | Australia | Direct - Phylogenetics | High |
| 102 | Matsumoto H, Mimura M. "Hyperbolic space of phylogenetic trees." *Journal of Theoretical Biology* | 2016 | Japan | Direct - Trees | Medium |
| 103 | Billera LN, et al. "Geometry of the space of phylogenetic trees." *Advances in Applied Mathematics* | 2001 | USA | Related - Tree geometry | Medium |
| 104 | Gori M, et al. "A new model of tree edit distance with moves." *IEEE TKDE* | 2016 | Italy | Related - Tree distance | Low |
| 105 | Zhou Y, et al. "Hyperbolic embeddings for learning options in reinforcement learning." *arXiv* | 2021 | USA | Related - RL | Low |

### 5.3 P-adic and Non-Archimedean Methods

| # | Citation | Year | Region | Relevance | Priority |
|---|----------|------|--------|-----------|----------|
| 106 | Khrennikov A. "p-Adic valued distributions in mathematical physics." *Springer* | 1994 | Russia/Sweden | Direct - P-adic physics | Medium |
| 107 | Dragovich B. "p-Adic and adelic cosmology." *arXiv* | 2007 | Serbia | Related - Cosmology | Low |
| 108 | Murtagh F. "On ultrametricity, data coding, and computation." *Journal of Classification* | 2004 | Ireland | Direct - Ultrametrics | Medium |
| 109 | Rammal R, et al. "Ultrametricity for physicists." *Reviews of Modern Physics* | 1986 | France | Related - Physics | Low |
| 110 | Bradley P. "Finding ultrametricity in data using topology." *arXiv* | 2008 | UK | Related - Topology | Low |

---

## Section 6: HIV Vaccine Development (15 Papers)

### 6.1 Vaccine Target Identification

| # | Citation | Year | Region | Relevance | Priority |
|---|----------|------|--------|-----------|----------|
| 111 | Barouch DH, et al. "Evaluation of a mosaic HIV-1 vaccine in a multicentre, randomised, double-blind, placebo-controlled, phase 1/2a clinical trial." *Lancet* | 2018 | USA | Direct - Mosaic | High |
| 112 | Korber B, et al. "T-cell vaccine strategies for HIV." *Human Vaccines & Immunotherapeutics* | 2020 | USA | Direct - T-cell vaccines | High |
| 113 | Stephenson KE, et al. "Immunogenicity of the Ad26.ENVA.01 HIV-1 vaccine candidate." *Journal of Infectious Diseases* | 2017 | USA | Direct - Ad26 | Medium |
| 114 | Fischer W, et al. "Polyvalent vaccines for optimal coverage of potential T-cell epitopes in global HIV-1 variants." *Nature Medicine* | 2007 | USA | Direct - Coverage | High |
| 115 | Gaschen B, et al. "Diversity considerations in HIV-1 vaccine selection." *Science* | 2002 | USA | Direct - Diversity | High |

### 6.2 Conserved Element Vaccines

| # | Citation | Year | Region | Relevance | Priority |
|---|----------|------|--------|-----------|----------|
| 116 | Letourneau S, et al. "Design and pre-clinical evaluation of a universal HIV-1 vaccine." *PLOS ONE* | 2007 | USA | Direct - Conserved | High |
| 117 | Mothe B, et al. "HIVconsv vaccines and romidepsin in early-treated HIV-1-infected individuals." *Journal of Infectious Diseases* | 2020 | Spain | Direct - HIVconsv | High |
| 118 | Borthwick N, et al. "Vaccine-elicited human T cells recognizing conserved protein regions inhibit HIV-1." *Molecular Therapy* | 2014 | UK | Direct - T cell vaccines | Medium |
| 119 | Ondondo B, et al. "Novel conserved-region T-cell mosaic vaccine with high global HIV-1 coverage." *Molecular Therapy* | 2016 | UK | Direct - Mosaic conserved | Medium |
| 120 | Kulkarni V, et al. "Altered response hierarchy and increased T-cell breadth upon HIV-1 conserved element DNA vaccination in macaques." *PLOS ONE* | 2014 | USA | Related - NHP | Medium |

### 6.3 Clinical Trials and Efficacy

| # | Citation | Year | Region | Relevance | Priority |
|---|----------|------|--------|-----------|----------|
| 121 | Rerks-Ngarm S, et al. "Vaccination with ALVAC and AIDSVAX to prevent HIV-1 infection in Thailand." *New England Journal of Medicine* | 2009 | Thailand | Direct - RV144 | High |
| 122 | Haynes BF, et al. "Immune-correlates analysis of an HIV-1 vaccine efficacy trial." *New England Journal of Medicine* | 2012 | USA | Direct - Correlates | High |
| 123 | Gray GE, et al. "Vaccine efficacy of ALVAC-HIV and bivalent subtype C gp120-MF59 in adults." *New England Journal of Medicine* | 2021 | South Africa | Direct - HVTN 702 | High |
| 124 | Johnson & Johnson. "Imbokodo HIV vaccine trial discontinued." *Press Release* | 2021 | Global | Related - Recent trial | Medium |
| 125 | Buchbinder SP, et al. "Efficacy assessment of a cell-mediated immunity HIV-1 vaccine." *Lancet* | 2008 | USA | Related - STEP trial | Medium |

---

## Section 7: Computational and Machine Learning Methods (15 Papers)

### 7.1 Deep Learning for Proteins

| # | Citation | Year | Region | Relevance | Priority |
|---|----------|------|--------|-----------|----------|
| 126 | Rives A, et al. "Biological structure and function emerge from scaling unsupervised learning to 250 million protein sequences." *PNAS* | 2021 | USA | Direct - ESM | High |
| 127 | Elnaggar A, et al. "ProtTrans: Towards cracking the language of life's code through self-supervised deep learning." *IEEE TPAMI* | 2022 | Germany | Direct - ProtTrans | High |
| 128 | Jumper J, et al. "Highly accurate protein structure prediction with AlphaFold." *Nature* | 2021 | UK | Direct - AlphaFold | High |
| 129 | Lin Z, et al. "Evolutionary-scale prediction of atomic level protein structure with a language model." *Science* | 2023 | USA | Direct - ESMFold | High |
| 130 | Bepler T, Berger B. "Learning protein sequence embeddings using information from structure." *ICLR* | 2019 | USA | Direct - Embeddings | Medium |

### 7.2 Machine Learning for Viral Evolution

| # | Citation | Year | Region | Relevance | Priority |
|---|----------|------|--------|-----------|----------|
| 131 | Hie B, et al. "Learning the language of viral evolution and escape." *Science* | 2021 | USA | Direct - Escape prediction | High |
| 132 | Maher MC, et al. "Predicting the mutational drivers of future SARS-CoV-2 variants of concern." *Science Translational Medicine* | 2022 | USA | Related - Variant prediction | Medium |
| 133 | Luksza M, Lässig M. "A predictive fitness model for influenza." *Nature* | 2014 | Germany | Direct - Fitness prediction | High |
| 134 | Louie RHY, et al. "Fitness landscape of the human immunodeficiency virus envelope protein." *Journal of Virology* | 2018 | Australia | Direct - HIV fitness | High |
| 135 | Ferguson AL, et al. "Translating HIV sequences into quantitative fitness landscapes predicts viral vulnerabilities for rational immunogen design." *Immunity* | 2013 | USA | Direct - Fitness landscape | High |

### 7.3 Sequence Analysis Methods

| # | Citation | Year | Region | Relevance | Priority |
|---|----------|------|--------|-----------|----------|
| 136 | Hopf TA, et al. "Mutation effects predicted from sequence co-variation." *Nature Biotechnology* | 2017 | USA/Germany | Direct - Co-variation | High |
| 137 | Riesselman AJ, et al. "Deep generative models of genetic variation capture mutation effects." *Nature Methods* | 2018 | USA | Direct - DeepSequence | High |
| 138 | Frazer J, et al. "Disease variant prediction with deep generative models of evolutionary data." *Nature* | 2021 | USA | Direct - EVE | High |
| 139 | Notin P, et al. "Tranception: protein fitness prediction with autoregressive transformers." *ICML* | 2022 | USA | Direct - Transformers | Medium |
| 140 | Meier J, et al. "Language models enable zero-shot prediction of mutation effects." *NeurIPS* | 2021 | USA | Direct - Zero-shot | Medium |

---

## Section 8: HIV Evolution and Epidemiology (10 Papers)

### 8.1 Global HIV Diversity

| # | Citation | Year | Region | Relevance | Priority |
|---|----------|------|--------|-----------|----------|
| 141 | Hemelaar J, et al. "Global and regional molecular epidemiology of HIV-1, 1990-2015." *AIDS* | 2019 | UK | Direct - Epidemiology | High |
| 142 | Bbosa N, et al. "HIV subtype diversity worldwide." *Current Opinion in HIV and AIDS* | 2019 | Uganda/UK | Direct - Subtypes | Medium |
| 143 | Ratmann O, et al. "Sources of HIV infection among men having sex with men and implications for prevention." *Science Translational Medicine* | 2016 | UK | Related - Transmission | Medium |
| 144 | Faria NR, et al. "The early spread and epidemic ignition of HIV-1 in human populations." *Science* | 2014 | Belgium/UK | Related - Origins | Medium |
| 145 | Ragonnet-Cronin M, et al. "Automated analysis of phylogenetic clusters." *BMC Bioinformatics* | 2013 | UK | Related - Clustering | Low |

### 8.2 Within-Host Evolution

| # | Citation | Year | Region | Relevance | Priority |
|---|----------|------|--------|-----------|----------|
| 146 | Zanini F, et al. "Population genomics of intrapatient HIV-1 evolution." *eLife* | 2015 | Germany | Direct - Within-host | High |
| 147 | Lemey P, et al. "Synonymous substitution rates predict HIV disease progression." *PLOS Computational Biology* | 2007 | Belgium | Direct - Synonymous | Medium |
| 148 | Maldarelli F, et al. "HIV latency. Specific HIV integration sites are linked to clonal expansion and persistence of infected cells." *Science* | 2014 | USA | Related - Integration | Medium |
| 149 | Immonen TT, et al. "Recombination enhances HIV-1 envelope diversity by facilitating the survival of latent genomes." *PLOS Computational Biology* | 2015 | USA | Related - Recombination | Medium |
| 150 | Lee GQ, et al. "Clonal expansion of genome-intact HIV-1 in functionally polarized Th1 CD4+ T cells." *Journal of Clinical Investigation* | 2017 | USA | Related - Reservoirs | Low |

---

## Section 9: Priority Reading Lists

### 9.1 Must-Read Papers (Top 20)

| Priority | Paper # | Topic | Why Essential |
|----------|---------|-------|---------------|
| 1 | 27 | HLA/Control | Pereyra - Genome-wide HLA |
| 2 | 52 | bnAbs | VRC01 discovery |
| 3 | 57 | bnAbs | Sok & Burton review |
| 4 | 81 | Tropism | geno2pheno method |
| 5 | 76 | Tropism | Original 11/25 rule |
| 6 | 1 | Resistance | Stanford HIVDB |
| 7 | 96 | Geometry | Poincaré embeddings |
| 8 | 26 | HLA/Control | Fellay GWAS |
| 9 | 131 | ML | Hie escape prediction |
| 10 | 135 | Fitness | Ferguson landscapes |
| 11 | 31 | CTL | Crawford B57 escape |
| 12 | 66 | Clinical | Caskey bnAb trial |
| 13 | 121 | Vaccine | RV144 trial |
| 14 | 128 | Structure | AlphaFold |
| 15 | 112 | Vaccine | Korber T-cell review |
| 16 | 15 | Resistance | Theys fitness costs |
| 17 | 62 | bnAbs | Landais breadth |
| 18 | 87 | Tropism | V3 function |
| 19 | 42 | CTL | Mothe protective targets |
| 20 | 6 | Resistance | geno2pheno resistance |

### 9.2 Papers by Region

**Africa (12 papers):** 29, 31, 38, 41, 62, 65, 123, 141, 142, ...
**Europe (35 papers):** 3, 6, 7, 8, 9, 10, 11, 18, 76, 77, 80, 81, 82, ...
**Asia (8 papers):** 44, 90, 102, 121, ...
**North America (80+ papers):** 1, 2, 4, 5, 26, 27, 51-75, ...
**Australia (5 papers):** 89, 101, 134, ...
**South America (3 papers):** Included in global studies

### 9.3 Papers by Year

**Classic (pre-2005):** 1, 2, 4, 29, 37, 38, 40, 76, 80, 103
**Foundational (2005-2015):** 26, 27, 31-36, 51-55, 81-83, 96, 121, 122
**Recent (2016-2020):** 3, 57, 58, 66-70, 97-100, 111-120, 126-130
**Current (2021-2025):** 70, 123, 124, 128, 129, 131-140

---

## Section 10: How to Analyze These Papers

### 10.1 For Each Paper, Record:

```
Citation:
Year:
Region:
Main Finding:
Relationship to Our Work:
  □ Confirms our finding
  □ Contradicts our finding
  □ Extends our finding
  □ Provides context
  □ Different methodology
Data Used:
Methods Used:
Key Figures/Tables:
Limitations Noted:
Future Directions Mentioned:
Potential Collaboration:
```

### 10.2 Synthesis Questions

For each section, answer:
1. What is the consensus in the field?
2. Where are controversies or gaps?
3. How do our findings fit?
4. What would strengthen our claims?
5. Who should we cite or contact?

---

## Section 11: Recommended Reading Order

### Week 1-2: Foundations
- Papers 1-5 (Resistance basics)
- Papers 76-77 (Tropism basics)
- Papers 26-30 (HLA/CTL basics)
- Papers 51-57 (bnAb basics)

### Week 3-4: Methods
- Papers 6-10 (Resistance prediction)
- Papers 81-85 (Tropism prediction)
- Papers 96-100 (Hyperbolic methods)
- Papers 126-130 (Deep learning)

### Week 5-6: Current State
- Papers 57-75 (bnAb current)
- Papers 111-125 (Vaccines)
- Papers 131-140 (ML current)

### Week 7-8: Integration
- Cross-reference with our findings
- Identify gaps and opportunities
- Draft literature review section

---

**Document Version:** 1.0
**Total Papers:** 150
**Last Updated:** December 25, 2025
